S&P 500 · Life Sciences (Contract Research) · Moderate-liquidity options · Large cap · ~$10B
Charles River operates the dominant outsourced preclinical CRO platform globally — a position built over 80 years that is extraordinarily difficult to replicate given the regulatory expertise, proprietary research model colonies, and deep customer relationships embedded in multi-year master service agreements. Every new drug candidate that enters development anywhere in the world either uses Charles River services or a tier-2 provider that competes on price rather than capability. After a severe biotech funding drought in 2023-2024 that crushed CRO demand, biotech funding is recovering with venture capital and IPO activity normalising — the lagged demand recovery will flow through CRL's revenue with a 6-12 month offset. At current valuations, CRL prices in permanent demand destruction rather than a cyclical trough.
This page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.
Every setup carries risk. Here's what could move CRL against you, plus the key stats that frame any position.
Charles River Laboratories (CRL) currently has an Amora Edge Score of 65/100, ranking it top 27% of today's scan. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.
CRL's historical win rate on closed Stoptions setups is 61%. Win rate is calculated as the percentage of past CRL trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.
The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.
Every 72 hours we refresh CRL's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If CRL drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.
The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to CRL: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is CRL outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. CRL currently scores 65.
CRL's sector rank and percentile against other Life Sciences (Contract Research) tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Life Sciences (Contract Research) Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.
Educational content only — not personalized investment advice. Options carry substantial risk.
Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.
No spam. One email Friday afternoon. Unsubscribe in one click.